Skip to main content
. 2022 Sep 3;23(1):114. doi: 10.1186/s10194-022-01489-7

Table 3.

Results of surgical procedures

MVD (%) SRS (%) GLYC (%) RFT (%) p
n 93 15 28 17
No of MDT (%) 0.445
1 84 (90.3) 11 (73.3) 22 (78.6) 14 (82.4)
2+ 9 (9.7) 4 (26.7) 6 (21.4) 3 (17.6)
Drug at first visit (%) 0.513
 Monotherapy 47 (50.5) 9 (60.0) 13 (46.4) 6 (35.3)
 No drugs 9 (9.7) 3 (20.0) 2 (7.1) 2 (11.8)
 Polytherapy 37 (39.8) 3 (20.0) 13 (46.4) 9 (52.9)
Length of follow up in years (mean (SD)) 2.53 (2.60) 4.09 (2.51) 4.14 (2.69) 3.16 (2.41) 0.017
Number reporting any complication 42 (45) 3 (20) 11 (39) 16 (94)
Pain (%) <0.001
 Pain free off drugs 64 (71.9) 2 (14.3) 10 (38.5) 8 (50.0)
 Pain free on drugs 8 (9.0) 5 (35.7) 7 (26.9) 0 (0.0)
 Mild pain 6 (6.7) 2 (14.3) 5 (19.2) 3 (18.8)
 Moderate pain 6 (6.7) 3 (21.4) 1 (3.8) 1 (6.2)
 Severe pain 5 (5.6) 2 (14.3) 3 (11.5) 4 (25.0)
Diagnosis= TN (%) 82 (88.2) 13 (86.7) 27 (96.4) 17 (100.0) 0.275
MS (%) 0 (0.0) 1 (6.7) 3 (10.7) 3 (17.6) 0.003
MDT to surgery in years (mean (SD) 0.67 (1.21) 2.03 (2.68) 1.37 (1.76) 1.04 (2.30) 0.014
Repeat surgery same 5 0 2 5
Repeat surgery other 7 5 7 0

MVD Microvascular decompression, SRS Stereotactic radiosurgery, GLYC Glycerol rhizotomy, RFT Radiofrequency thermocoagulation, TN Trigeminal neuralgia, MS Multiple sclerosis